Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 02, 2022 11:00 ET | Source: G1 Therapeutics

Data Presented at ASCO Demonstrate Trilaciclib Helps Protect Against Severe Neutropenia, Severe Anemia, and Severe Thrombocytopenia When Given to Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Patients Prior to Chemotherapy

- Patients Receiving Trilaciclib Experienced a Lower Incidence of Single-Lineage and Multilineage Chemotherapy-Induced Myelosuppressive Events Compared with Patients Receiving Placebo - - Total...
June 02, 2022 10:26 ET | Source: Wall Street Reporter

BioMed Stocks On the Move: PDSB, NMLSF, TNXP, AIMLF; Leaders Report Latest Advances in Antiviral Vaccines, Novel Therapeutics for Oncology, and Autism and HealthTech Wearables

NEW YORK, June 02, 2022 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEO’s of: Tonix...
June 02, 2022 09:00 ET | Source: Rénibus Therapeutics Inc.

Renibus Therapeutics Expands Leadership Team, Announces Appointments of New Chief Financial Officer and Chief Medical Officer

Jamie Donadio appointed Chief Financial Officer and Bhupinder Singh, MD, appointed Chief Medical Officer Appointments bring more than 40 combined years of proven leadership, clinical and commercial...
June 02, 2022 09:00 ET | Source: Sorrento Therapeutics, Inc.

Scilex Holding Company, a Sorrento Company, announces continued growth in ZTlido® in managed health care plans

Earlier this year, a national pharmacy benefit manager (PBM) moved a large percentage of its patients from not covered to covered, adding access to ZTlido for 5.5 million lives. ZTlido is now covered...
June 02, 2022 09:00 ET | Source: Oncternal Therapeutics

Oncternal Therapeutics to Participate in the Jefferies Healthcare Conference 2022

SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
June 02, 2022 08:58 ET | Source: Gradalis, Inc.

Gradalis Appoints Steven Engle as Chief Executive Officer

DALLAS, June 02, 2022 (GLOBE NEWSWIRE) -- Gradalis, a late-stage stage biotechnology company developing immunotherapies for multiple cancer indications, announced today that Steven Engle has joined...
June 02, 2022 08:30 ET | Source: Vaxart, Inc.

Vaxart Reports Positive Preliminary Data from the Phase 1b Trial of its Oral Norovirus Vaccine Candidates in Elderly Adults

Results support safety and immunogenicity of the vaccine candidate in the highly vulnerable elderly population Preliminary boost study data also reported Norovirus has been estimated to...
June 02, 2022 08:15 ET | Source: VectivBio AG

VectivBio Announces First Two Patients Dosed in Phase 2 STARGAZE Study of Apraglutide for the Treatment of Acute Graft-versus-Host Disease

– Interim proof-of-concept data anticipated from STARGAZE in H1 2023 – First-in-class regenerative, non-immunosuppressive approach to treating acute Graft-versus-Host Disease – Second clinical...
June 02, 2022 08:05 ET | Source: TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals to Present at the Jefferies Healthcare Conference

SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
June 02, 2022 08:00 ET | Source: Ayala Pharmaceuticals

Ayala Pharmaceuticals to Present at the 2022 Jefferies Global Healthcare Conference

REHOVOT, Israel and WILMINGTON, Del., June 02, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small...